Market Place
Sourcing Support
FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments
This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s
Emcure’s Import Alert: Is there a way of knowing who will be next?
The U.S.
FDA banned drug imports from the finished dosage form operations of Emcure
Pharmaceutic
